|
|
Improving the quality of people's lives
Lek, a Sandoz company, is one of the pillars of leading world
generics company Sandoz. It operates as a global development center
for products and technologies, as a global manufacturing center for
active pharmaceutical ingredients and medicines, as a competence
center for the development of vertically integrated products, as a
Sandoz competence center in the field of development and manufacturing
of biopharmaceutical products and as a supply center for the markets
of CEE, SEE and CIS, sales Slovenia and sales services for Sandoz's
global markets. Lek d.d. has more than 2.400 employees in Slovenia.
Sandoz, a Division of the Novartis group, is a global leader in the
field of generic pharmaceuticals, offering a wide array of high-quality,
affordable products that are no longer protected by patents. Sandoz has a
portfolio of more than 950 compounds and sells its products in more than 130
countries. Key product groups include antibiotics, treatments for central
nervous system disorders, gastrointestinal medicines, cardiovascular treatments
and hormone therapies. Sandoz develops, produces and markets these medicines
along with pharmaceutical and biotechnological active substances and
anti-infectives. In addition to strong organic growth in recent years, Sandoz
has made a series of acquisitions including Lek (Slovenia), Sabex (Canada),
Hexal (Germany) and EonLabs (US) In 2007, Sandoz employed around 23,000 people
worldwide and posted sales of USD 7.2 billion.
Novartis AG provides healthcare solutions that address the evolving
needs of patients and societies. Focused solely on growth areas in healthcare,
Novartis offers a diversified portfolio to best meet these needs: innovative
medicines, cost-saving generic pharmaceuticals, preventive vaccines and
diagnostic tools, and consumer health products. Novartis is the only company
with leading positions in these areas. In 2007, the Group's continuing
operations (excluding divestments in 2007) achieved net sales of USD 38.1
billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was
invested in R&D activities throughout the Group. Headquartered in Basel,
Switzerland, Novartis Group companies employ approximately 98,200 full-time
associates and operate in over 140 countries around the world. For more
information, please visit www.novartis.com .
|
|
